EGFR and non-small cell lung carcinoma: With the clinical application of targeted drugs against EGFR, ALK, ROS1, MET, NTRK mutations, and immune checkpoint inhibitors against PD‐L1/PD‐1, the overall survival of advanced NSCLC patients has been significantly prolonged.3, 4